Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

The use of antibody induction after kidney transplantation has increased from 25% to 63% in the past decade and roughly one half of the induction agent used is anti-interleukin-2 receptor antibody (IL-2RA, ie, basiliximab or daclizumab). When combined with calcineurin inhibitor (CNI)-based immunosup...

Descripción completa

Detalles Bibliográficos
Autores principales: Sageshima, Junichiro, Ciancio, Gaetano, Chen, Linda, Burke, George W
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726067/
https://www.ncbi.nlm.nih.gov/pubmed/19707418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726067/
https://www.ncbi.nlm.nih.gov/pubmed/19707418

Ejemplares similares